Taihua Plc Renewal of Drug Production Permit (0591N)
26 Janvier 2016 - 4:20PM
UK Regulatory
TIDMTAIH
RNS Number : 0591N
Taihua Plc
26 January 2016
Taihua plc
("Taihua" or the "Company")
Renewal of Drug Production Permit
The Company confirms today that the renewal of its Drug
Production Permit ("DPP") has been granted ahead of the previously
advised timescales. The Company understands that the processing of
the DPP application was accelerated following a number of
representations by the Company's management to Shaanxi Provincial
Food and Drug Administration. The new DPP remains in force until 31
December 2020.
As the Company now has the DPP and the Good Manufacturing
Practice ("GMP") certificate, the regulatory restrictions on the
Company's manufacture and sale of Homoharringtonine and its
Traditional Chinese Medicine ("TCM") products have now been lifted.
The Company does not anticipate that this short delay will have had
any impact on the Company's businesses.
Following the renewal of the DPP, it is the intention of the
Company to attempt to recover more market share in
Homoharringtonine in China. It also intends to continue its
strategy of expansion of TCM products distribution, particularly
Bian Tong Pian.
Enquiries:
Nicholas Lyth, Taihua plc 07769 906 686
Katy Mitchell/Nick Prowting, WH Ireland Limited +44 161 832 2174
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSESFIMFMSEEF
(END) Dow Jones Newswires
January 26, 2016 10:20 ET (15:20 GMT)
Taihua (LSE:TAIH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Taihua (LSE:TAIH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Taihua (London Stock Exchange): 0 recent articles
Plus d'articles sur Taihua